The global histology and cytology market is expected to grow at a CAGR of around 13.2% from 2020 to 2027 and expected to reach the market value of around US$ 26.3 Bn by 2027.
Histology is the detailed study of biological tissue of human, animal, and plant origin that is primarily used in life science research for biology, medicine, veterinary medicine, and many other sub-disciplines. Prior to examination by microscope technology of so-called "sections" of a specific tissue, staining is required to highlight and enhance the contrast of biological structures within the tissue. Stains are commonly used for examining bulk tissues (e.g. highlighting muscle fibers or connective tissue), identifying cell populations (e.g., classifying different blood cells), highlighting organelles within individual cells, and many other applications. Cytology is the study of cells that deals with the chemistry, function, and structure of the cells under investigation. Both disciplines have evolved into a standard discipline in life science research after becoming an inherent part of the in-vitro diagnostics (IVD) and in-vivo diagnostics markets.
What's new in Histology and Cytology Market?
Big calls for "Histology and Cytology" in Diagnosis of Cancer
Historically, histopathology and cytopathology were the primary tools used in cancer diagnosis. According to a Cancer Council Australia report, these techniques have evolved from a time when tumors were diagnosed using haematoxylin and eosin (H&E) stained slides to the current routine evaluation of tumors using immunocytochemistry (IHC) to confirm tumor histogenesis and subtype. In the case of breast cancer, this entails routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors), as well as HER2 expression and Ki67 expression (a marker of tumor proliferation). These factors have a significant impact on prognosis and the selection of anti-cancer treatments. In addition, molecular histopathology using in-situ hybridization (ISH) techniques provides additional information that influences prognosis and treatment in breast cancer and other cancers. Gene profiling technology has recently been used to define subgroups of breast cancer patients. It has identified, for example, the Luminal-A breast cancer subtype for which adjuvant chemotherapy is unlikely to be beneficial. These gene profiling techniques will most likely be used in the treatment of other tumors in the coming years.
Technological advancements bolster the growth of global histology and cytology market
Histopathologists provide cancer diagnostic services; they handle the cells and tissues removed from suspicious "lumps and bumps," identify the nature of the abnormality, and, if malignant, inform the clinician about the type of cancer, its grade, and, in some cases, its responsiveness to specific treatments. Biopsy tissue can now be obtained from previously inaccessible sites such as the pancreas or retroperitoneum using sophisticated imaging techniques (behind the peritoneum, the membrane lining the abdominal cavity). Tissue is then processed for an extended period of time, usually overnight, before being examined under a microscope. The specimen can be examined immediately in certain limited circumstances using special techniques. Pathologists are leading the way with new techniques such as "fluorescence in-situ hybridization" in the face of rapidly changing developments in molecular pathology. Furthermore, (FISH) and polymerase chain reaction (PCR) are used to map the genetic material in tissues or tumors, which is critical in the treatment of many cancers. Cytology, on the other hand, has made remarkable progress in the diagnosis of lung cancer in recent years. According to the Indian Academy of Cytologists, lung cancer can be diagnosed in two ways: histopathological and cytopathological. Cytology specimens are increasingly being used for both primary diagnosis and ancillary studies in lung cancer. One of the most effective strategies in the diagnosis of benign and malignant pulmonary lesions is the use of cytological methods. Respiratory tract cytology is now widely available around the world as an important diagnostic procedure in the evaluation of suspected lung lesions. Exfoliative (induced sputum), abrasive cytology [bronchoalveolar lavage (BAL), BW, BB], and FNA cytology are all available for receiving specimens for cytological evaluation of lung lesions thanks to the flexible fiberoptic bronchoscope (endobronchial ultrasound guided, transesophageal).
Increasing standardization of pathological laboratories through government funding and support fuel the growth of global market
Oxford University Hospitals (OUH) is one of the NHS trusts that will benefit from a US$16.22 Mn national funding boost to improve cellular pathology services and provide faster and more accurate cancer diagnosis. The PathLAKE (Pathology Image Data Lake for Analytics Knowledge and Education) digital pathology consortium, led by University Hospital in Coventry and including OUH, is one of three government-funded initiatives developing artificial intelligence (AI) to diagnose disease. The funding that we and our regional partners have received will allow us to proceed with full network digitization in this program.
The global histology and cytology market is segmented based on type of examination, product, and application. By type of examination, the market is classified into histology and cytology. Histology is further segmented as microscopic technique, immunohistochemistry, molecular pathology, and cryostat & microtomy. Cytology is further segmented as breast cancer, cervical cancer, bladder cancer, lung cancer, and other cancers. By product, the market is bifurcated into instruments and analysis software system and consumable and reagents. Based on application, the market is segregated as drug discovery & designing, clinical diagnostics, and research.
Based on the type of examination, the cytology segment is expected to dominate the global histology and cytology market. Segment growth can be attributed to the incorporation of Artificial Intelligence (AI) for developing advanced cytology systems. Consumables and reagents are expected to have a dominant market share during the forecast period. Tissue sample containers, kits, stain reagents, fixative solutions, medium reagents, and other reagents are among the consumables used in histology and cytology. The large share of the segment can be attributed primarily to the widespread use of histology and cytology consumables. The drug discovery and designing segment is expected to dominate the global histology and cytology market in terms of application. During the forecast period, the segment is expected to maintain its dominance. The segment's expansion can be attributed to the widespread use of histomorphometry and IHC staining in pharmaceutical and biotechnology firms for drug development.
The global histology and cytology market is expected to be dominated by North America. The region's growth can be attributed to a number of factors, including a high incidence of cancer, extensive R&D activities, the presence of key players, and established research infrastructure for pathology services.
Asia Pacific, on the other hand, is expected to have the fastest growing CAGR in the global histology and cytology market during the forecast period. The region's growth can be attributed to a variety of factors, including increased cancer awareness, a large target population, and improved healthcare infrastructure.
The prominent players of the global histology and cytology market involve Hologic, Inc., Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific, Inc., Danaher Corporation, Sysmex Corporation, Trivitron, Koninklijke Philips N.V., and among others
Market By Type Of Examination
Market By Product
Instruments and Analysis Software System
Consumable and Reagents
Market By Application
Drug Discovery & Designing
Histology and cytology market is expected to reach a market value of around US$ 26.3 Bn by 2027.
The histology and cytology market is expected to grow at a CAGR of around 13.2% from 2020 to 2027.
Based on type of examination, cytology segment is the leading segment in the overall market.
Technological advancements is one of the prominent factors that drive the demand for histology and cytology market.
Hologic, Inc., Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific, Inc., Danaher Corporation, Sysmex Corporation, Trivitron, Koninklijke Philips N.V., and among others.
North America is anticipated to grab the highest market share in the regional market
Asia Pacific is expected to be the fastest growing market in the forthcoming years